查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1833551

2032 年先進製藥市場預測：按配方類型、藥物類型、治療領域、技術、最終用戶和地區進行的全球分析

Advanced Drug Formulation Market Forecasts to 2032 - Global Analysis By Formulation Type (Oral, Injectable, Topical, Transdermal, Inhalation, Nasal, and Implantable), Drug Type, Therapeutic Area, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球先進製藥市場預計在 2025 年達到 1.9 兆美元，到 2032 年將達到 2.9 兆美元，預測期內的複合年成長率為 6.1%。

先進製劑涉及開發有效且安全地遞送藥物化合物的創新方法。這包括緩釋性、標靶遞送和增溶等技術。這些製劑可增強療效、減少給藥頻率並提高患者遵從性。所用技術包括脂質體、微球、奈米顆粒和經皮系統。此過程整合了藥物動力學、材料科學和工程學，以最佳化口服、注射和局部等各種給藥途徑的藥物穩定性、吸收和生物有效性。

據Pharma Intelligence稱，先進的配方可提高藥物的穩定性、溶解度和輸送能力，從而實現緩釋性、奈米封裝和個人化醫療方面的突破。

慢性病增多

在全球範圍內，癌症、心血管疾病和糖尿病等慢性疾病的發生率不斷上升，推動了對先進藥物製劑的需求。這些疾病需要創新的治療方案，以提高生物有效性、確保控制釋放並改善患者依從性。在對標靶性和個人化治療方法的需求推動下，製藥公司正在大力投資先進的製劑技術。這種勢頭正在改變藥物輸送方式，推動市場成長，並強化市場的長期擴張軌跡。

研發和監管成本高

儘管成長前景光明，但由於高昂的研發成本和複雜的法律規範，市場面臨巨大的限制。先進的製劑通常涉及複雜的輸送系統、生物製藥整合和奈米技術，推高了製造成本。此外，監管核准需要大量的臨床試驗，這延長了核准週期並增加了不確定性。這些財務和合規負擔尤其影響小型生技公司，限制了它們的擴張能力。因此，成本和核准障礙對創新製劑的全球應用構成了重大挑戰。

兒科和老年用藥製劑快速成長

針對兒科和老年族群的先進製劑需求日益成長，蘊藏著巨大的商機。由於吞嚥障礙、代謝差異和服藥依從性問題，這些病患小組通常難以適應傳統劑型。受這些需求的驅動，口溶錠、咀嚼片和緩釋系統等創新製劑正日益受到青睞。製藥公司正在積極利用以患者為中心的製劑策略來拓展這一細分市場。這些由人口結構驅動的變化預計將加速藥物的採用和市場成長。

兒童和老年人申請數量快速成長

市場面臨的一大威脅是專利頻繁到期，這為學名藥製造商的強勢進入鋪平了道路。這加劇了價格競爭，降低了品牌藥的利潤率。此外，學名藥由於價格低廉，尤其是在成本敏感的地區，往往能迅速被接受。這種動態迫使創新企業持續投資於產品線開發。如果無法透過創新配方實現差異化，品牌藥公司可能會失去市場佔有率，並威脅到其長期永續性。

COVID-19的影響：

新冠疫情對先進製藥市場產生了雙重影響。一方面，全球供應鏈中斷和臨床試驗延遲阻礙了研發進程。另一方面，這場危機加速了對創新藥物遞送方法的需求，尤其是疫苗和抗病毒療法。各公司以前所未有的速度採用mRNA製劑和新型遞送系統，樹立了新的效率標準。這段變革時期凸顯了先進製藥在應對全球衛生緊急情況及其他領域的重要性。

預計口腔護理市場在預測期內將佔據最大佔有率

預計口服藥物領域將在預測期內佔據最大的市場佔有率，這得益於患者用藥便利性、高依從性和成本效益。緩釋片、口溶錠和奈米口服藥物等先進劑型正在鞏固該領域的市場地位。慢性病口服藥物的激增進一步推動了該領域的應用。製藥公司正優先考慮該領域的技術創新，以最大限度地提高治療效果。因此，預計口服藥物領域將在未來幾年佔據最大的市場佔有率。

生物製藥領域預計將在預測期內以最高的複合年成長率成長

受標靶治療、單株抗體和細胞療法需求成長的推動，生技藥品領域預計將在預測期內實現最高成長率。這些複雜的分子需要複雜的配方策略來維持穩定性、有效性和控制釋放。在生物技術和精準醫療的推動下，生技藥品領域正獲得強勁發展動能。對生物相似藥和下一代生物生技藥品的持續投資預計將進一步推動其擴張。因此，預計該領域將在預測期內實現最高的複合年成長率。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大市場佔有率，這得益於醫療保健支出的不斷成長、患者人數的龐大以及製藥業的快速擴張。中國、印度和日本等國家正在加強其研發基礎設施，以吸引全球投資。此外，文明病的日益普及以及政府的支持政策正在推動先進製劑的採用。綜合來看，這些因素使亞太地區成為先進製劑領域的主導者。

複合年成長率最高的地區：

北美地區憑藉其強大的創新能力、先進的醫療基礎設施以及支持新藥研發的健全法律規範，預計將在預測期內呈現最高的複合年成長率。該地區匯聚了許多大型製藥和生物技術公司，致力於投資下一代藥物傳輸技術。此外，生技藥品需求的不斷成長，加上慢性病的高發生率，正在加速其應用。在優惠的保險報銷政策的推動下，高階療法的快速普及也推動了成長。因此，北美將成為成長最快的區域市場。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球先進製藥市場（按製劑類型）

  • 口服
  • 注射
  • 外用
  • 經皮
  • 吸入
  • 鼻腔
  • 嵌入式

6. 全球先進製藥市場（依藥物類型）

  • 小分子
  • 生物製藥
  • 疫苗
  • 胜肽
  • 基於核酸的
  • 生物相似藥
  • 學名藥

7. 全球先進製藥市場（依治療領域）

  • 腫瘤學
  • 心血管系統
  • 神經病學
  • 感染疾病
  • 免疫學
  • 內分泌學
  • 罕見疾病

8. 全球先進製藥市場（按技術）

  • 奈米科技
  • 脂質體遞送
  • 持續釋放
  • 控釋
  • 定向投放
  • 固體分散體

9. 全球先進製藥市場（依最終用戶分類）

  • 醫院
  • 製藥公司
  • 生技公司
  • 研究辦公室
  • 診所
  • 合約研究組織
  • 學術機構

第 10 章全球先進製藥市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Gilead Sciences
  • Merck & Co.
  • Novartis
  • Pfizer
  • AbbVie
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Bayer
  • Sanofi
  • Amgen
  • Celgene
  • Johnson & Johnson
  • Regeneron Pharmaceuticals
Product Code: SMRC31384

According to Stratistics MRC, the Global Advanced Drug Formulation Market is accounted for $1.9 trillion in 2025 and is expected to reach $2.9 trillion by 2032 growing at a CAGR of 6.1% during the forecast period. Advanced drug formulation involves the development of innovative methods to deliver pharmaceutical compounds effectively and safely. It includes techniques like sustained release, targeted delivery, and solubility enhancement. These formulations improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance. Technologies used include liposomes, microspheres, nanoparticles, and transdermal systems. The process integrates pharmacokinetics, material science, and engineering to optimize drug stability, absorption, and bioavailability across various routes of administration, including oral, injectable, and topical.

According to Pharma Intelligence, advanced formulations enhance drug stability, solubility, and delivery, enabling extended-release, nanoencapsulation, and personalized medicine breakthroughs.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The rising global burden of chronic illnesses such as cancer, cardiovascular disorders, and diabetes is driving strong demand for advanced drug formulations. These conditions require innovative therapeutic solutions that enhance bioavailability, ensure controlled release, and improve patient adherence. Fueled by the need for targeted and personalized treatment approaches, pharmaceutical companies are investing heavily in advanced formulation technologies. This momentum is reshaping drug delivery practices, fostering growth, and strengthening the market's long-term expansion trajectory.

Restraint:

High R&D and regulatory costs

Despite promising growth, the market faces significant restraints from high research and development expenditures and complex regulatory frameworks. Advanced formulations often involve sophisticated delivery systems, biologics integration, and nanotechnology, which escalate production costs. Additionally, regulatory approvals demand extensive clinical trials, prolonging timelines and raising uncertainty. These financial and compliance burdens particularly impact smaller biotech firms, limiting their ability to scale. Consequently, cost and approval barriers pose notable challenges to wider adoption of innovative drug formulations globally.

Opportunity:

Pediatric and geriatric applications surge

A promising opportunity lies in the growing demand for advanced formulations tailored to pediatric and geriatric populations. These patient groups often face difficulties with conventional dosage forms due to swallowing challenges, metabolic differences, or adherence issues. Spurred by this need, innovations such as orally disintegrating tablets, chewable forms, and sustained-release systems are gaining traction. Pharmaceutical companies are actively leveraging patient-centric formulation strategies to tap into this segment. This demographic-driven shift is poised to accelerate adoption and market growth.

Threat:

Pediatric and geriatric applications surge

A key threat to the market stems from frequent patent expirations, opening the door for generic drug manufacturers to enter aggressively. This intensifies price competition and reduces the profit margins for branded advanced formulations. Moreover, generic alternatives often gain rapid acceptance due to affordability, especially in cost-sensitive regions. Spurred by these dynamics, innovative firms must continuously reinvest in pipeline development. Failure to differentiate with novel formulations risks market share erosion, threatening long-term sustainability of branded players.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the advanced drug formulation market. On one hand, disruptions in global supply chains and delayed clinical trials hindered R&D progress. On the other, the crisis accelerated demand for innovative drug delivery methods, particularly in vaccines and antiviral therapies. Companies adopted mRNA formulations and novel delivery systems at unprecedented speed, setting new benchmarks for efficiency. This transformative phase underscored the importance of advanced formulations in addressing global health emergencies and beyond.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to account for the largest market share during the forecast period, driven by patient convenience, high compliance, and cost-effectiveness. Advanced formulations such as extended-release tablets, orally disintegrating tablets, and nano-enabled oral drugs are strengthening this segment's market position. The surge in chronic disease therapies delivered orally further enhances its adoption. Pharmaceutical firms are prioritizing innovations in this route to maximize therapeutic efficacy. Consequently, the oral segment is projected to secure the largest market share in the coming years.

The biologics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biologics segment is predicted to witness the highest growth rate, due to rising demand for targeted therapies, monoclonal antibodies, and cell-based treatments. These complex molecules require sophisticated formulation strategies to maintain stability, efficacy, and controlled release. Propelled by advancements in biotechnology and precision medicine, the biologics segment is gaining strong momentum. Ongoing investments in biosimilars and next-generation biologics will further fuel expansion. As a result, this segment is expected to record the highest CAGR in the forecast horizon.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to rising healthcare expenditures, a large patient pool, and rapid pharmaceutical manufacturing expansion. Countries such as China, India, and Japan are strengthening their R&D infrastructure and attracting global investments. Furthermore, increasing prevalence of lifestyle-related diseases and supportive government initiatives enhance adoption of advanced formulations. Collectively, these factors solidify Asia Pacific's dominance in the advanced drug formulation landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR fueled by robust innovation, advanced healthcare infrastructure, and strong regulatory frameworks supporting new formulations. The region is home to leading pharmaceutical and biotech companies investing in next-generation drug delivery technologies. Moreover, rising demand for biologics, coupled with high chronic disease incidence, accelerates adoption. Supportive reimbursement policies and rapid uptake of premium therapies further boost growth. Consequently, North America will be the fastest-growing regional market.

Key players in the market

Some of the key players in Advanced Drug Formulation Market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, Merck & Co., Novartis, Pfizer, AbbVie, Boehringer Ingelheim, F. Hoffmann-La Roche, Bayer, Sanofi, Amgen, Celgene, Johnson & Johnson, and Regeneron Pharmaceuticals.

Key Developments:

In Aug 2025, AstraZeneca unveiled a breakthrough nanoparticle-based inhalable asthma therapy, engineered for rapid onset and enhanced pulmonary deposition. This innovation targets chronic respiratory patients, ensuring superior drug delivery efficiency, faster symptom relief, and improved long-term disease management outcomes.

In July 2025, Pfizer introduced an advanced dual-release oral capsule for rheumatoid arthritis, combining immediate and sustained release mechanisms. This novel design improves patient adherence, minimizes disease flare-ups, and ensures consistent therapeutic control, enhancing long-term outcomes for chronic arthritis sufferers.

In June 2025, Novartis launched a pioneering temperature-stable injectable biologic for oncology, formulated to withstand challenging storage conditions. By extending shelf life and eliminating cold-chain dependence, it broadens accessibility, particularly in low-resource settings, ensuring reliable cancer care worldwide.

Formulation Types Covered:

  • Oral
  • Injectable
  • Topical
  • Transdermal
  • Inhalation
  • Nasal
  • Implantable

Drug Types Covered:

  • Small Molecules
  • Biologics
  • Vaccines
  • Peptides
  • Nucleic Acid-Based
  • Biosimilars
  • Generic Drugs

Therapeutic Areas Covered:

  • Oncology
  • Cardiovascular
  • Neurology
  • Infectious Diseases
  • Immunology
  • Endocrinology
  • Rare Diseases

Technologies Covered:

  • Nanotechnology
  • Liposomal Delivery
  • Sustained Release
  • Controlled Release
  • Targeted Delivery
  • Solid Dispersions

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Laboratories
  • Clinics
  • Contract Research Organizations
  • Academic Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Advanced Drug Formulation Market, By Formulation Type

  • 5.1 Introduction
  • 5.2 Oral
  • 5.3 Injectable
  • 5.4 Topical
  • 5.5 Transdermal
  • 5.6 Inhalation
  • 5.7 Nasal
  • 5.8 Implantable

6 Global Advanced Drug Formulation Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Small Molecules
  • 6.3 Biologics
  • 6.4 Vaccines
  • 6.5 Peptides
  • 6.6 Nucleic Acid-Based
  • 6.7 Biosimilars
  • 6.8 Generic Drugs

7 Global Advanced Drug Formulation Market, By Therapeutic Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Cardiovascular
  • 7.4 Neurology
  • 7.5 Infectious Diseases
  • 7.6 Immunology
  • 7.7 Endocrinology
  • 7.8 Rare Diseases

8 Global Advanced Drug Formulation Market, By Technology

  • 8.1 Introduction
  • 8.2 Nanotechnology
  • 8.3 Liposomal Delivery
  • 8.4 Sustained Release
  • 8.5 Controlled Release
  • 8.6 Targeted Delivery
  • 8.7 Solid Dispersions

9 Global Advanced Drug Formulation Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Biotechnology Firms
  • 9.5 Research Laboratories
  • 9.6 Clinics
  • 9.7 Contract Research Organizations
  • 9.8 Academic Institutions

10 Global Advanced Drug Formulation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Bristol-Myers Squibb
  • 12.3 Eli Lilly
  • 12.4 Gilead Sciences
  • 12.5 Merck & Co.
  • 12.6 Novartis
  • 12.7 Pfizer
  • 12.8 AbbVie
  • 12.9 Boehringer Ingelheim
  • 12.10 F. Hoffmann-La Roche
  • 12.11 Bayer
  • 12.12 Sanofi
  • 12.13 Amgen
  • 12.14 Celgene
  • 12.15 Johnson & Johnson
  • 12.16 Regeneron Pharmaceuticals

List of Tables

  • Table 1 Global Advanced Drug Formulation Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Advanced Drug Formulation Market Outlook, By Formulation Type (2024-2032) ($MN)
  • Table 3 Global Advanced Drug Formulation Market Outlook, By Oral (2024-2032) ($MN)
  • Table 4 Global Advanced Drug Formulation Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 5 Global Advanced Drug Formulation Market Outlook, By Topical (2024-2032) ($MN)
  • Table 6 Global Advanced Drug Formulation Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 7 Global Advanced Drug Formulation Market Outlook, By Inhalation (2024-2032) ($MN)
  • Table 8 Global Advanced Drug Formulation Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 9 Global Advanced Drug Formulation Market Outlook, By Implantable (2024-2032) ($MN)
  • Table 10 Global Advanced Drug Formulation Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 11 Global Advanced Drug Formulation Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 12 Global Advanced Drug Formulation Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 13 Global Advanced Drug Formulation Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 14 Global Advanced Drug Formulation Market Outlook, By Peptides (2024-2032) ($MN)
  • Table 15 Global Advanced Drug Formulation Market Outlook, By Nucleic Acid-Based (2024-2032) ($MN)
  • Table 16 Global Advanced Drug Formulation Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 17 Global Advanced Drug Formulation Market Outlook, By Generic Drugs (2024-2032) ($MN)
  • Table 18 Global Advanced Drug Formulation Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 19 Global Advanced Drug Formulation Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Advanced Drug Formulation Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 21 Global Advanced Drug Formulation Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 22 Global Advanced Drug Formulation Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Advanced Drug Formulation Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 24 Global Advanced Drug Formulation Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 25 Global Advanced Drug Formulation Market Outlook, By Rare Diseases (2024-2032) ($MN)
  • Table 26 Global Advanced Drug Formulation Market Outlook, By Technology (2024-2032) ($MN)
  • Table 27 Global Advanced Drug Formulation Market Outlook, By Nanotechnology (2024-2032) ($MN)
  • Table 28 Global Advanced Drug Formulation Market Outlook, By Liposomal Delivery (2024-2032) ($MN)
  • Table 29 Global Advanced Drug Formulation Market Outlook, By Sustained Release (2024-2032) ($MN)
  • Table 30 Global Advanced Drug Formulation Market Outlook, By Controlled Release (2024-2032) ($MN)
  • Table 31 Global Advanced Drug Formulation Market Outlook, By Targeted Delivery (2024-2032) ($MN)
  • Table 32 Global Advanced Drug Formulation Market Outlook, By Solid Dispersions (2024-2032) ($MN)
  • Table 33 Global Advanced Drug Formulation Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Advanced Drug Formulation Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Advanced Drug Formulation Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 36 Global Advanced Drug Formulation Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 37 Global Advanced Drug Formulation Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 38 Global Advanced Drug Formulation Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 39 Global Advanced Drug Formulation Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
  • Table 40 Global Advanced Drug Formulation Market Outlook, By Academic Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above. Introduction